By Tony Fong

NEW YORK (GenomeWeb News) – With little fanfare, Johnson & Johnson is building out its capabilities in the molecular diagnostics space with a focus on circulating tumor cells and companion diagnostics development.

In recent interviews with GenomeWeb Daily News, officials from several J&J businesses outlined a strategy focused on continuing to build out the firm's CellSearch technology as well as the development of a next-generation CTC technology in collaboration with Massachusetts General Hospital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.